1
Targeted but Substantial Rollbacks of the U.S. Childhood Vaccine Schedule
Possible
Discussed by: Reuters, The Washington Post, Time, vaccine policy analysts quoted in major outlets
Under this scenario, the Trump–Kennedy team uses the new memo and ACIP’s reconstituted membership to narrow or delay several vaccines deemed low-priority or controversial, beyond hepatitis B. COVID-19 shots remain non-routine for most children, universal birth dosing for hepatitis B is eliminated, and additional changes could include later timing or risk-based recommendations for HPV, some boosters, and certain combination vaccines. The White House frames these changes as bringing the U.S. closer to Denmark, Japan, or Germany, and as part of a broader MAHA push to cut ‘unnecessary’ medical exposures. This outcome becomes more likely if the CDC director formally adopts the hepatitis B change, if MAHA’s vaccine framework gains political traction, and if early disease upticks are modest enough to be explained away or blamed on other causes.
2
Symbolic Review, Minimal Structural Change
Likely
Discussed by: Some public health experts interviewed by U.S. media and advocacy groups
Here, political and professional backlash from medical societies, state health departments, and parts of Congress constrain the administration’s ambition. The formal ‘review’ cites differences in foreign schedules but emphasizes local disease patterns and health-system gaps, leading to only limited changes beyond hepatitis B and the already-implemented COVID-19 shift. The memo becomes a talking point for the base, but insurers, states, and professional groups mostly keep the broader schedule intact in practice. This scenario would be reinforced if large pediatric systems, state immunization programs, and insurers quietly continue covering and recommending the full schedule, and if courts or Congress signal potential pushback against more radical departures.
3
Fragmented Patchwork: States and Professional Bodies Set De Facto Standard
Possible
Discussed by: State-level health officials, AAP leadership, legal scholars
In this outcome, the federal schedule weakens, but states, medical societies, and insurers respond by building their own reference standards. AAP and key states (e.g., California, Illinois, New York, some blue-leaning or public health–focused jurisdictions) continue to recommend universal hepatitis B birth doses, broad COVID-19 eligibility, and existing schedules for MMR, DTaP, and HPV. Other states use the new federal flexibility to roll back mandates for school entry. The result is a highly fragmented map of childhood vaccine expectations, with differential disease risk and school policies depending on geography. This scenario would be driven by rapid state-level legislative activity, high-profile outbreaks in low-vaccination states, and growing divergence between AAP and CDC recommendations.
4
Backlash After Outbreaks Forces Reversal and Rebuilding of Trust
Uncertain
Discussed by: Epidemiologists and historians citing DPT and MMR precedents, major health media
If reductions in coverage driven by the hepatitis B and other changes lead to visible outbreaks—such as increases in pediatric hepatitis B, measles, or whooping cough—public opinion could swing sharply. Historical experience shows that severe or fatal cases in infants can trigger rapid political reaction. A future administration or a re-aligned Congress could then move to restore or even strengthen federal recommendations and firewall scientific advisory bodies from political interference. However, rebuilding trust after years of mixed messages from CDC and HHS, and after online misinformation campaigns, would likely take many years and require structural reforms, not just policy reversals.
